- |||||||||| Fraxiparine (nadroparin) / Aspen Pharma
Journal: Case Report: A successful outcome of nadroparin calcium therapy for cerebral venous sinus thrombosis in a child with acute lymphoblastic leukemia. (Pubmed Central) - Sep 25, 2024 We present the case of a 13-year-old boy with ALL who developed CVST and intrinsic hemorrhage approximately 30?days after receiving chemotherapy with vincristine, dexamethasone, daunorubicin, and pegylated-asparaginase (PEG-Asp)...Oxcarbazepine and clonazepam were started with good seizure control...Oral acetazolamide (500-1,000?mg, daily) was administered to relieve headache and reduce intracranial pressure...Nadroparin calcium therapy appears to be safe and effective for pediatric CVST with ALL. The reintroduction of Erwinia Asp should be accompanied by anticoagulant therapy with nadroparin calcium.
- |||||||||| Review, Journal: Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers. (Pubmed Central) - Sep 8, 2024
We conclude that there is strong variance in the pharmacological effects of these drugs, and in the available information. At present, GS967 and riluzole can be regarded bona fide INaP blockers, while phenytoin and lacosamide are blockers that only act on the slowly inactivating component of sodium currents.
- |||||||||| levetiracetam / Generic mfg., topiramate / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Clinical study of the effect of 5 kinds of antiepileptic drugs on the postictal state. (Pubmed Central) - Aug 21, 2024 Levetiracetam, lamotrigine, oxcarbazepine, topiramate, and valproate demonstrate favorable efficacy in ameliorating the severity of post-seizure condition. Further investigations are warranted to assess the potential of other widely employed anti-seizure medications in enhancing post-seizure status.
- |||||||||| oxcarbazepine / Generic mfg.
Journal: Hot water epilepsy with alone and spontaneous seizures in childhood. (Pubmed Central) - Aug 18, 2024 Changing bath room habits did not improve the treatment as a first line management, all the patients except one used antiepileptic drug treatment. Until now, there has been no study in Turkey showing the frequency of HWE exclusively in children.
- |||||||||| Austedo (deutetrabenazine) / Teva
Chorea Acanthocytosis Misdiagnosed as Functional Movement Disorder (Poster Hall (Exhibit Hall A)) - Aug 9, 2024 - Abstract #MDSCongress2024MDS_Congress_1521; The diagnostic challenges encountered were due to motor manifestations overshadowed by psychological symptoms. Our case highlights the importance of genetic testing for young patients with chorea and chronic psychiatric symptoms.
- |||||||||| Clinical, Journal: Comparison Table: Some oral antiseizure medications. (Pubmed Central) - Jul 29, 2024
In conclusion, through zebrafish-aided screening, our study identified four drugs that can be repurposed to induce AML differentiation, thus providing new agents for AML therapy. No abstract available
- |||||||||| Review, Journal: Drugs for epilepsy. (Pubmed Central) - Jul 29, 2024
No abstract available No abstract available
- |||||||||| Trigeminal Neuralgia with Autonomic Symptoms (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_2220;
The presence of autonomic symptoms in suspected TN cases necessitates careful reevaluation to distinguish from SUNCT/SUNA, particularly when carbamazepine response is suboptimal. Accurate differentiation is crucial for targeted therapy, as medication efficacy varies significantly between these conditions.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Medical Cannabinoids Therapy in Refractory Post-Herpetic Neuralgia and Recurrent Uveitis (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1274; This patient had debilitating pain, which interfered with her daily activities and ability to work. CBD was used as a third line agent, as is currently recommended by the Canadian guidelines for neuropathic pain (5), where this patient was treated by an experienced pain specialist with training in clinical pharmacology (MO).
- |||||||||| Review, Journal: The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy. (Pubmed Central) - Jul 13, 2024
They are starting with those proving their protective effect and ending with those confirming disturbances in the oxidation-reduction balance. The presented publication reviews the state of knowledge on the role of oxidative stress in the most frequently used therapies for neuropsychiatric diseases using first- and second-generation antipsychotic drugs, i.e., haloperidol, clozapine, risperidone, olanzapine, quetiapine, or aripiprazole, mood stabilizers: lithium, carbamazepine, valproic acid, oxcarbazepine, and antidepressants: citalopram, sertraline, and venlafaxine, along with a brief pharmacological characteristic, preclinical and clinical studies effects.
- |||||||||| Zavzpret (zavegepant nasal spray) / Pfizer, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Review, Journal: An update on pharmacotherapy for trigeminal neuralgia. (Pubmed Central) - Jun 13, 2024 Third-generation anticonvulsants, new calcitonin gene-related peptide blockers for migraine, and older drugs such as ketamine and cannabinoids may be promising adjuvants or monotherapeutic options...Combination therapy might allow for lower doses of carbamazepine or oxcarbazepine, thus reducing the number and severity of potential adverse events but the potential for pharmacokinetic drug-drug interactions must be considered. Drug therapy for trigeminal neuralgia involves acute or abortive treatments, often administered in hospital versus long-term preventive therapy, usually involving oral agents.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma
PK/PD data, Journal, Real-world evidence, Real-world: Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: A real-world study. (Pubmed Central) - Jun 11, 2024 Drug therapy for trigeminal neuralgia involves acute or abortive treatments, often administered in hospital versus long-term preventive therapy, usually involving oral agents. In this study, we captured the pharmacokinetic/pharmacodynamic characteristics of PER in pediatric epilepsy patients through analysis of real-world data and adopted a pharmacometric approach to support an individualized dosing strategy for PER in this specific population.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Diacomit (stiripentol) / Biocodex, Meiji Seika, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Journal, Adverse events: An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database. (Pubmed Central) - Jun 6, 2024 These drugs included diazepam, brivaracetam, gabapenetin, and pregabalin. Although several limitations are present with the FAERS database, it is imperative to closely monitor patient comorbidities for increased risk of suicidality with the use of several ASMs.
- |||||||||| levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
PK/PD data, Retrospective data, Review, Journal: The impact of pregnancy on the pharmacokinetics of antiseizure medications: A systematic review and meta-analysis of data from 674 pregnancies. (Pubmed Central) - Jun 3, 2024 Although several limitations are present with the FAERS database, it is imperative to closely monitor patient comorbidities for increased risk of suicidality with the use of several ASMs. Data for lamotrigine, oxcarbazepine (and monohydroxycarbazepine) and levetiracetam demonstrate major changes in pharmacokinetics during pregnancy, suggesting the importance of therapeutic drug monitoring to assist clinicians in optimizing treatment outcomes.
- |||||||||| aspirin / Generic mfg., levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Retrospective data, Journal: Retrospective Analysis of Presymptomatic Treatment In Sturge-Weber Syndrome. (Pubmed Central) - May 15, 2024 Presymptomatic treatment is a promising approach to children diagnosed with SWS prior to seizure onset. Further study is needed, including prospective drug trials, long-term neuropsychological outcome, and prospective EEG analysis to assess this approach and determine biomarkers for presymptomatic treatment.
- |||||||||| carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Review, Journal: Hyponatremia With Anticonvulsant Medications: A Narrative Review. (Pubmed Central) - May 6, 2024 Choosing a treatment option should include consideration of the drug causing the electrolyte disturbance, the patient's risk factor profile, and the severity of symptoms as they present in the individual patient. Healthcare providers should be aware of hyponatremia as a potential side effect of ASMs, the signs and symptoms of hyponatremia,
- |||||||||| phenytoin / Generic mfg., oxcarbazepine / Generic mfg.
Anticonvulsant Hypersensitivity Syndrome (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_2481; Since there are still no strict diagnostic criteria for AHS, the combination of clinical and laboratory features that appeared within 3 months after starting an anticonvulsant helps us establish the diagnosis. The risk of developing severe convulsions as a result of the immediate interruption of the culprit drug and the use of alternative drugs often requires special treatment and care.
- |||||||||| Journal: Diabetic Peripheral Neuropathy: Prevention and Treatment. (Pubmed Central) - Apr 8, 2024
First-line drug therapy for painful diabetic peripheral neuropathy includes duloxetine, gabapentin, amitriptyline, and pregabalin; however, these medications do not restore sensation to affected extremities...Second-line drug therapy includes nortriptyline, imipramine, venlafaxine, carbamazepine, oxcarbazepine, topical lidocaine, and topical capsaicin...Peripheral transcutaneous electrical nerve stimulation is well tolerated and inexpensive, but benefits are modest. Other treatments, such as acupuncture, alpha-lipoic acid, acetyl-L-carnitine, cannabidiol, and onabotulinumtoxinA need further study in patients with diabetic peripheral neuropathy.
- |||||||||| levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Sudden Cardiac Death or Ventricular Arrythmia in Patients Taking Levetiracetam or Oxcarbazepine. (Pubmed Central) - Apr 5, 2024 When compared with oxcarbazepine, levetiracetam does not correlate with increased risk of ventricular arrythmia and sudden cardiac death. Our finding does not support the concern for cardiac risk to indicate restriction of levetiracetam use nor the requirement of cardiac monitoring when using it.
- |||||||||| oxcarbazepine / Generic mfg.
PK/PD data, Journal: Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: Model-based dose optimization. (Pubmed Central) - Mar 20, 2024 The probability to obtain target trough concentration ranges (TTCRs) of MHD between 3 and 35?mg/L was determined by Monte Carlo simulations for doses ranging from 8 to 90?mg/kg/day. A new dose optimization strategy combining the dosage guidelines and Bayesian method provides a tailored approach for Chinese paediatric epileptic patients based on their individual BW and desired TTCRs of MHD, and also supports current dose recommendations, with the exception of children weighing ?5
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma
Journal, HEOR, Compliance: Treatment compliance, treatment patterns, and healthcare utilization in epilepsy patients with first add-on antiepileptic drugs: A nationwide cohort study. (Pubmed Central) - Mar 19, 2024 Furthermore, perampanel showed the lowest HCRU and costs for all-cause cases as well as the lowest length of stay and outpatient visits for epilepsy-related cases. In this population-based study, the use of lamotrigine, levetiracetam, oxcarbazepine, or perampanel as the first add-on therapy in patients with epilepsy contributed to better treatment compliance and lower HCRU and costs than that of carbamazepine, topiramate, or valproate.
|